public health and costs, public and private insurances, and community. Only pharmaceutical industry has major financial gains from the clinical routine use of highly expensive targeted “therapy”. Perhaps a few patients may benefit. Nevertheless, the vast majority of patients experience an unnecessary overtreatment with potential adverse effects [1, 2].
Why is it illusion to expect any benefit from generalization, unselected treatment strategy using the currently available targeted drugs? What are the genetic variation-based convincing data that accumulating proves now the need for a revolution in discovery drugs research arena and randomized trials design? Why and how quantitative genetics, personal genomics and systems biology [3- 6] represent the most rational scientific approaches to achieve the major goal of a patient-tailored management of solid cancers?